Rx Market Caps–the Flip Side: From Public-to-Private Investment
This article was originally published in Start Up
Executive Summary
This month, we compared valuations for those biotech companies which had both gone public in '95 or '96 and had, in 1998, completed a round of private financing. As the amounts of private money raised got larger, so too did market cap valuations. One major reason: the larger the valuation, the more investors are willing to invest.